Filing Details

Accession Number:
0001209191-21-004672
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-21 16:34:30
Reporting Period:
2021-01-19
Accepted Time:
2021-01-21 16:34:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1761612 Bicycle Therapeutics Plc BCYC Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1776938 Kevin Lee C/o Bicycle Therapeutics Plc
B900, Babraham Research Campus
Cambridge X0 CB22 3AT
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2021-01-19 4,529 $29.14 260,556 No 4 S Direct
Ordinary Shares Disposition 2021-01-19 371 $30.22 260,185 No 4 S Direct
Ordinary Shares Disposition 2021-01-19 100 $31.09 260,085 No 4 S Direct
Ordinary Shares Disposition 2021-01-20 734 $31.33 259,351 No 4 S Direct
Ordinary Shares Disposition 2021-01-20 100 $32.02 259,251 No 4 S Direct
Ordinary Shares Disposition 2021-01-20 351 $33.00 258,900 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Shares sold pursuant to a Rule 10b5-1 trading plan.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.